表紙
市場調查報告書
商品編碼
236763

遺傳基因檢驗的全球市場

Genetic Testing

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 573 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告以遺傳基因檢驗的全球市場為焦點,依產品市場區隔 (產前及新生兒遺傳基因檢驗藥理基因學檢驗,預測診斷) 及地區 (美國,加拿大,日本,歐洲,亞太地區,其他) 別檢驗·預測2014-2020年這段期間之交易金額,並彙整過去7年的市場過程分析和大小86家參與企業公司的簡介等目前競爭環境相關的調查資訊。

第1章 簡介,調查方法,產品定義

  • 調查的可靠性和報告的限制
  • 免責聲明
  • 資料的解釋和報告作成層級
    • 定量技術與分析
  • 產品的定義和調查範圍
    • 產前及新生兒遺傳基因檢驗藥理遺傳基因檢驗,藥理基因學檢驗
    • 預測診斷

第2章 摘要整理

  • 全球市場概要
    • 概要基礎知識
    • 全球10大遺傳基因障礙
    • 遺傳基因檢驗-宣告新時代的到來
    • 穩固定制醫療地位的遺傳基因檢驗
    • 全球人口膨脹帶來的成長機會擴大
    • 因人口高齡化而加速的遺傳基因檢驗市場
    • 因醫療支出的提高促使需求大幅增加
    • 遺傳基因檢驗-正在急速發展對體外診斷(IVD)市場而言不可或缺的因素
    • 遺傳基因檢驗-分子診斷市場的急速成長市場區隔
    • 遺傳檢驗的進步相關之生物標記的發現
    • 美國食品藥物管理局核準的癌症生物標記一覽
  • 市場區隔考察
    • 興起的產前檢查
    • 各現象,表現症狀,盛行率別之遺傳基因障礙一覽
    • 產前檢查-改變妊娠治療世界之物
    • 產前檢查-基本的概要
    • 可利用的產前篩檢及診斷法的症狀別一覽
    • 傳統的產前診斷技術-伴隨危險性的工作
    • 激化的胎兒染色體檢驗(NIPD)市場上的競爭
    • 排除傳統診斷法的危險性和不確定性之胎兒染色體檢驗
    • 對胎兒染色體檢驗法的異議-普及的一大難關
    • 產前檢查的優點和阻礙普及的倫理問題
    • 優點超越潛在性障礙的胎兒染色體檢驗
    • 影響胎兒染色體檢驗普及的主要係數
    • 胎兒染色體檢驗可望用途的多樣性
    • 預測診斷
    • 穩定擴大的乳癌遺傳基因檢驗市場
    • 多元化的遺傳學-乳癌檢驗中不容置疑的第一領域
    • 例行性臨床試驗 vs.預測遺傳基因檢驗
    • CDD發生數·盛行率的擴大-主要成長推動要素
    • 預測診斷不可或缺的新型生物標記的發現
    • 未解決的問題 一以遺傳基因疾病為對象的遺傳基因診斷和檢驗廣泛實施之妨礙
    • 遺傳基因諮詢師的不足-對預測遺傳基因測試市場而言的一大障礙
    • 藥理基因學的發展為遺傳基因檢驗市場成長帶來吉兆
  • 市場趨勢
    • 門診病人(Direct-to-Consumer)遺傳基因檢驗-遺傳基因檢驗市場上主要趨勢
    • 製作新企業的平台
    • 門診病人遺傳基因檢驗經營者的經營模式
    • 擴大門診病人遺傳基因檢驗的知名度- 優劣點
    • 胚胎著床前遺傳基因診斷(PGD)-遺傳基因檢驗市場主要推動材料
    • 全基因譯解-在遺傳基因檢驗的功與過
    • 興起的老年癡呆症患者遺傳基因檢驗的有效性
    • wafarin研究目的遺傳基因檢驗的效用
    • 腫瘤學-遺傳基因檢驗基礎重點領域
    • 遺傳基因檢驗同時也具有助於中樞神經系統疾病治療的可能性
    • 神經退化性疾病-遺傳基因檢驗市場代表性重點領域
    • 老年癡呆症
    • 亨丁頓舞蹈症
    • 遺傳基因檢驗-囊狀纖維化症不可或缺的工具
    • 組織適合性檢驗
    • 次世代定序 - 基因譯解巨大的一步
    • 兒童遺傳基因檢驗讓成人期發病疾病篩檢急速獲得支持
    • 需要改善的全球遺傳基因檢驗產業之安全性規定
    • 面臨的課題
    • 遺傳諮詢 -提升的機會
    • 透過線上的措施
    • 因ACOG (The American congress of obstetricians and gynecologists) 及 ACGM (Advisory Committee on Genetic Modification) 推薦而擴大的囊狀纖維化症檢驗的需求
    • 倫理問題和恰當的法規政策之必要性
    • 肥胖的遺傳基因檢驗相關問題點
    • 妊娠期的診斷和治療-減少梅毒相關的死亡·死產的有效的方法
  • 分子診斷市場 - 考察
    • 急速成長轉向的全球分子診斷
    • 因自動化加速的全球市場
    • 分子診斷-多方面的技術融合所形成
    • 急速發展的傳染病分子診斷市場
    • 人口高齡化,疾病發生-成長基礎的推動要素
    • 視分子診斷市場為自家公司專門領域之醫藥品廠商
    • 訂製針對適當疾病的適當治療
    • 透過第三方機關的有限醫療報酬-障礙
    • 促使臨床結果提升的疾病特定型分子診斷
    • 分子診斷和智慧財產權
    • 不久的將來的商機
    • 醫療訓練及診療行為的課題
    • 對著眼於分子診斷的企業整體而言的障礙
    • 產品行銷 -商業性成功關鍵
    • 合併分子診斷的治療
    • 分子診斷-從集中化轉換到分權化
    • 分子診斷市場競爭環境
    • 其他值得注意的企業和各公司的不同市場區隔競爭地位
    • 著眼於未滿足需求的新加入企業
  • 產品概要
    • 遺傳基因檢驗相關的開場白
    • 遺傳基因檢驗及其使用目的
    • 候補遺傳基因與基因區分
    • 遺傳基因的DNA晶片
    • 遺傳基因變異的檢測所採用的技術
    • 遺傳基因檢驗的種類
    • 產前診斷
    • 癌症篩檢
    • 保原因者檢測
    • 新生兒診察
    • 預測實驗
    • 發病前檢驗
    • 細胞遺傳學檢驗
    • 遺傳基因檢驗流程的階段
    • 規定
    • 風險之外細胞遺傳學檢驗的規定
    • 遺傳基因檢驗的得到好處的醫療機關
    • 藥物遺傳學,藥理基因學
    • 代表性遺傳基因檢驗檢討
    • 囊狀纖維化症
    • 乳癌及卵巢癌症 (BRCA)
    • 老年癡呆症
    • 大腸癌症
    • 血鐵沉著症 (HH)
    • Cowden氏病
    • 亨丁頓舞蹈症
    • 有代表性的檢驗的費用
    • 遺傳基因檢驗的技術
    • 信號放大技術
    • 定量即時PCR分析
    • 非PCR法
    • 其他信號放大技術
    • DNA探針利用產品
  • 產品銷售·技術創新
  • 最新產業趨勢
  • 全球主要加入企業
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 其他歐洲各國
  • 亞太地區
  • 其他地區

第4章 競爭環境

目錄
Product Code: MCP-1392

Abstract:

Global Genetic Testing Market to Reach $17.3 Billion by 2026

Genetic testing broadly refers to the analysis of genes by examining genetic material taken from cells in a person`s blood sample, or a sample of other body fluids. The growing accessibility and acceptance of non-targeted sequencing among patients and consumers is expected to provide a major stimulus to the market. Applications such as tumor molecular profiling like liquid biopsies to select cancer treatment, non-invasive prenatal diagnostics, and sequencing for diagnosis of rare disease hold tremendous value. The market is poised to benefit from growing popularity of DTC testing for specific health risks like 3 BRCA mutations. Another driver for the market is proliferation of hybrid laboratories combining DTC and conventional laboratories.

Amid the COVID-19 crisis, the global market for Genetic Testing estimated at US$10.6 Billion in the year 2020, is projected to reach a revised size of US$17.3 Billion by 2026, growing at a CAGR of 8.6% over the analysis period. Prenatal & Newborn, one of the segments analyzed in the report, is projected to record a 8.8% CAGR and reach US$6.4 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Diagnostic segment is readjusted to a revised 8.2% CAGR for the next 7-year period. Globally, prenatal testing market is expected to rise due to the increasing risk of chromosomal abnormalities associated with increasing maternal age. One of the key growth drivers for new born and prenatal genetic testing is increased awareness about different chromosomal and genetic disorders. Development of healthcare technologies like HTS and next generation sequencing has helped detection of a number of abnormalities at early stages. Diagnostic genetic testing detects the presence of a certain genetic disease, like Huntington`s disease or cystic fibrosis through the detection of specific gene alteration.

The U.S. Market is Estimated at $4.7 Billion in 2021, While China is Forecast to Reach $1.2 Billion by 2026

The Genetic Testing market in the U.S. is estimated at US$4.7 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2026 trailing a CAGR of 10.8% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.2% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR. The US is the largest market for genetic testing worldwide. Insurance coverage for all types of genetic testing has increased, and this combined with the factor of significant reductions in genetic testing costs, is expected to result in stronger growth for the market in the years ahead. The market is also witnessing strong regulatory support especially for DTC-genetic testing. Growth in the Europe market is being driven by increasing healthcare expenditure and growing autoimmune diseases prevalence. Asia-Pacific region is expected to witness robust growth due to increasing disposable incomes, and expanding healthcare availability.

Predictive & Presymptomatic Segment to Reach $3 Billion by 2026

Predictive diagnostics is rapidly assuming importance owing to the increasing awareness and growth in preventive medicine. Development in predictive diagnostics is also a result of the growing interest in personalized medicine. Breast cancer diagnosis is one of the key end-use markets targeted by developers of predictive diagnostics. Presymptomatic tests determine the susceptibility of an individual in future, irrespective of his/her existing health condition. In the global Predictive & Presymptomatic segment, USA, Canada, Japan, China and Europe will drive the 9.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$2.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$169.2 Million by the year 2026.

Select Competitors (Total 249 Featured) -

  • 23andMe, Inc.
  • Abbott Laboratories
  • AutoGenomics, Inc.
  • Biocartis NV
  • BioRad Laboratories
  • Cepheid Inc.
  • ELITech Group SAS
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Natera, Inc.
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics, Inc.
  • Roche Diagnostics AG
  • Roche Molecular Diagnostics, Inc.
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • A Prelude to Genetic Testing
    • Top Ten Genetic Diseases Worldwide
    • Different Types of Genetic Tests include
    • Prenatal and Newborn Screening
    • Diagnostic Testing
    • Predictive & Presymptomatic Testing
    • Carrier Identification
    • Pharmacogenomic Testing
    • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
    • Genetic Testing Delivery Models
    • Genetic Sequencing Approaches
    • Genetic Testing Market Witnesses Sluggish Growth during COVID-19, Set to Record Exponential Growth Post-COVID
    • Expanding Applications to Drive Genetic Testing Market
    • Regional Landscape
    • Prenatal Testing Market to Rise
    • Market Outlook
  • 2. FOCUS ON SELECT PLAYERS
    • Recent Market Activity
    • World Brands
    • Innovations
  • 3. MARKET TRENDS & DRIVERS
    • Studies Indicate Possible Correlation between Genetic Variations Tied to Immunity and COVID-19 Severity
  • SEGMENT ANALYSIS
    • Prenatal Testing - Changing the World of Pregnancy Care
    • List of Available Prenatal Screening and Diagnostic Tests by Indication
    • Players in the Prenatal and New Born Genetic Testing Market
    • Conventional Invasive Pre-Natal Diagnostic Techniques - A Risky Affair
    • Emergence of Non-Invasive Prenatal Diagnosis (NIPD)
    • Competition Intensifies in the NIPD Market
    • Select Commercially Available NIPD (Genetic) Tests for Aneuploidy in the US
    • Strain on Resources Prevent Wide Adoption of Expanded Carrier Sequencing
    • Predictive Diagnostics
    • Breast Cancer Gene Testing Market to Expand Strongly
    • Myriad Genetics - A Leader in Breast Cancer Testing
    • Discovery of Novel Biomarkers Crucial to Predictive Diagnostics
    • Pharmacogenomics Development Augurs Growth of Genetic Testing Market
  • MARKET TRENDS AND GROWTH DRIVERS
    • Genetic Testing Paves the Way for Personalized Medicine
    • TABLE 1: Drug Ineffectiveness for Select Therapeutic Categories - Necessitating Personalized Medic
    • Next-Generation Sequencing (NGS) - A Giant Leap in Genome Sequencing
    • Biomarker Discovery Leads to Advanced Genetic Testing
    • Select List of Available Tumor Markers
    • Immense Popularity of Ancestry Testing
    • Increasing Focus on Data Churning
    • Genetic Testing to Explode into Provider Workflow with Intriguing Use Cases
    • Primary Factors Responsible for Waning Interest in Direct-to Consumer Genetic Testing
    • Liquid Biopsy to Facilitate Cancer Diagnosis and Treatment
    • Hybrid Labs to Bridge Gap Between Traditional and DTC Models
    • Rising Prevalence of Cancer and Chromosomal Disorders Augments Demand for Cell-Free DNA Testing
    • Emergence of Rapid DNA Testing
    • Oncology - A Key Focus Area for Genetic Testing
    • EXHIBIT 1: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Ageing Demographics to Drive Demand for Genetic Testing
    • EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Genetic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Prenatal & Newborn by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Prenatal & Newborn by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Diagnostic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Diagnostic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Predictive & Presymptomatic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Predictive & Presymptomatic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Carrier by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Carrier by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Pharmacogenomic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Pharmacogenomic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Genetic Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Genetic Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 31: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 32: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • Use of Genomic Data in Clinical Settings to Gather Pace
    • The United States: Leading Market for Genetic Testing Globally
    • Predictive Screening: Another Growth Area
    • Growing Relevance of Personalized Medicine Augurs Well
    • Rising Incidence of Cancer in the US: Driver for Cancer Genetic Testing
    • Estimated Number of New Cancer Cases and Deaths in the US (2019)
    • Newborn Testing Gains Ground
    • Invasive Prenatal Diagnosis Gives Way to Non-Invasive Prenatal Testing
    • Coverage of NIPT in Average Risk Pregnancies Expands Target Market
    • Direct-to-Consumer Testing: A Growing Market
    • Favorable Reimbursement Policies
    • Favorable Insurance Coverage for Cystic Fibrosis Genetic Testing
    • Demographic Changes Offer Growth Opportunities
    • TABLE 14: North American Aging Population by Age Group: 1975-2050
    • Skepticism Limits Widespread Adoption of Genetic Testing
    • Competitive Overview
    • Myriad Eyes Diversification and Expansion for Growth
    • Natera Holds Fort in the NIPT Market
    • Invitae Banks on Low Cost Solutions for Expanding Revenues
    • Regulatory Environment
    • Genetic Information Nondiscrimination Act Boosts Genetic Testing
    • Stricter Regulations for DTC Genetic Testing
    • FDA Attempts to Put a Leash around Unapproved DTC Genetic Tests
    • Select Genetic Test Reimbursement Codes
    • Market Analytics
    • TABLE 34: USA Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: USA 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • Rising Incidence of Chronic Diseases Spurs Genetic Testing Demand
    • Number of New Cancer Cases in Canada: 2019
    • Regulatory Scenario
    • Market Analytics
    • TABLE 40: Canada Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Canada 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • Demographics Drive Market Growth
    • DTC Genetic Testing Regulatory Scenario
    • TABLE 46: Japan Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Japan 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • Market Overview
    • China Attracts Domestic and Foreign Players
    • Strong Focus on Genomics
    • Genetic Testing to Reveal Real Talent in Children - A New Popular Application
    • China to Take Lead in Rapidly Growing Asian Genomics Market
    • Market Analytics
    • TABLE 52: China Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: China 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Aging Population to Drive Demand for Genetic Testing
    • TABLE 28: European Population by Age Group (2016, 2030 & 2050): Percentage Share Breakdown by Age Group for 0-14, 15-64, and 65 & Above
    • Legislations/Regulatory Policies in Select European Countries
    • Legislations Governing Genetic Testing in Select European Countries
    • Rising Cancer Incidence Augurs Well for European Genetic Testing Market
    • Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018
    • TABLE 58: Europe Current & Future Analysis for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Genetic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Genetic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 64: Europe Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 67: France Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: France Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: France 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 70: France Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: France Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: France 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • Parliamentary Regulations
    • TABLE 73: Germany Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Germany Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Germany 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 76: Germany Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Germany Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Germany 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 79: Italy Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Italy Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Italy 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 82: Italy Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Italy Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Italy 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • Increased Support for Personalized Medicine to Drive Genetic Testing
    • SMIP for Pharmacogenomic Testing
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Principles for DTC Genetic Testing Laid out by HGC
    • TABLE 85: UK Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: UK Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: UK 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 88: UK Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: UK Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: UK 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 91: Rest of Europe Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 94: Rest of Europe Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Europe Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Europe 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • Healthcare Spending in Asia-Pacific: On the Rise
    • India
    • Australia and New Zealand
    • Market Analytics
    • TABLE 97: Asia-Pacific Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 100: Asia-Pacific Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Asia-Pacific Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Asia-Pacific 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • Predictive Screening: Another Growth Area
    • Market Analytics
    • TABLE 103: Rest of World Current & Future Analysis for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of World Historic Review for Genetic Testing by Type - Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of World 15-Year Perspective for Genetic Testing by Type - Percentage Breakdown of Value Sales for Prenatal & Newborn, Diagnostic, Predictive & Presymptomatic, Carrier, Pharmacogenomic and Other Types for the Years 2012, 2020 & 2027
    • TABLE 106: Rest of World Current & Future Analysis for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Rest of World Historic Review for Genetic Testing by Application - Cancer, Genetic Disease, Cardiovascular Disease and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Rest of World 15-Year Perspective for Genetic Testing by Application - Percentage Breakdown of Value Sales for Cancer, Genetic Disease, Cardiovascular Disease and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 249